- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Longeveron Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| Mi | Longeveron receives China patent for stem cell potency assay | 5 | Investing.com | ||
| Mi | Longeveron erhält chinesisches Patent für Testverfahren von Stammzellen | 1 | Investing.com Deutsch | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Mi | Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | 1 | GlobeNewswire (USA) | ||
| 24.03. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | 933 | GlobeNewswire (Europe) | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen | |
| 17.03. | Longeveron Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Closing of Private Placement of up to $30 Million | 6 | GlobeNewswire (USA) | ||
| 11.03. | A $30 Million Reason to Buy Penny Stock Longeveron Today | 6 | Barchart.com | ||
| 10.03. | Longeveron secures $15M financing, eyes $15M more on trial results | 5 | Investing.com | ||
| 25.02. | Longeveron publishes phase 2b stem cell trial results in journal | 3 | Investing.com | ||
| 25.02. | Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell | 511 | GlobeNewswire (Europe) | MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic... ► Artikel lesen | |
| 13.02. | Longeveron ernennt Stephen Willard vor entscheidenden Studienergebnissen zum neuen CEO | 2 | Investing.com Deutsch | ||
| 13.02. | Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results | 2 | Investing.com | ||
| 13.02. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Longeveron Appoints Stephen H. Willard as Chief Executive Officer | 246 | GlobeNewswire (Europe) | Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant... ► Artikel lesen | |
| 13.02. | Longeveron appoints new CEO | 1 | Seeking Alpha | ||
| 05.02. | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 43,695 | 0,00 % | CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen | |
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,165 | +1,53 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,305 | -0,55 % | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| SOL GLOBAL INVESTMENTS | 0,020 | 0,00 % | XFRA 9SB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSOL GLOBAL INVESTM.... ► Artikel lesen | |
| TRINITY BIOTECH | 0,700 | +0,34 % | Trinity Biotech plc: Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test | Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,054 | -0,75 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,154 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,360 | +1,64 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,545 | +1,35 % | ANAVEX LIFE SCIENCES CORP in stabiler Marktphase | ||
| BIOAGE LABS | 13,830 | +0,29 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen | |
| CERUS | 1,600 | 0,00 % | Cerus Corporation: DRK Blood Donation Service Baden-Württemberg - Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT Blood System in Routine Clinical Practice | Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg Hessen and its subsidiary organization, the German... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,400 | +1,69 % | Ovid Therapeutics: H.C. Wainwright verdoppelt Kursziel auf 4 $ | ||
| LINEAGE CELL THERAPEUTICS | 1,246 | -2,66 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,035 (+3,10 %) liegt der Kurs bei 1,165 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.